BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22211510)

  • 1. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
    Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
    Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
    Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    Elenkova A; Shabani R; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
    Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
    Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study.
    Nachtigall LB; Valassi E; Lo J; McCarty D; Passeri J; Biller BM; Miller KK; Utz A; Grinspoon S; Lawson EA; Klibanski A
    Clin Endocrinol (Oxf); 2010 Jan; 72(1):53-8. PubMed ID: 19508591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.
    Herring N; Szmigielski C; Becher H; Karavitaki N; Wass JA
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):104-8. PubMed ID: 19128367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
    Kars M; Pereira AM; Bax JJ; Romijn JA
    Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cabergoline in hyperprolactinemia and valvular heart disease].
    Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
    Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor β1 is not a reliable biomarker for valvular fibrosis but could be a potential serum marker for invasiveness of prolactinomas (pilot study).
    Elenkova A; Atanassova I; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2013 Sep; 169(3):299-306. PubMed ID: 23801826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.
    Stiles CE; Lloyd G; Bhattacharyya S; Steeds RP; Boomla K; Bestwick JP; Drake WM
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e711-e720. PubMed ID: 33247916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
    Caputo C; Prior D; Inder WJ
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Vallette S; Serri K; Serri O
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?
    Gu H; Luck S; Carroll PV; Powrie J; Chambers J
    Clin Endocrinol (Oxf); 2011 May; 74(5):608-10. PubMed ID: 21198745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.
    Vallette S; Serri K; Rivera J; Santagata P; Delorme S; Garfield N; Kahtani N; Beauregard H; Aris-Jilwan N; Houde G; Serri O
    Pituitary; 2009; 12(3):153-7. PubMed ID: 18594989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
    Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
    Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
    Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists.
    Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
    Cardiovasc Ther; 2011 Dec; 29(6):404-10. PubMed ID: 20553285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.